Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]
In development [GID-TA10110] Expected publication date: TBC
Search results
492 results
-
-
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
In development [GID-TA10164] Expected publication date: TBC
-
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
In development [GID-TA10065] Expected publication date: TBC
-
Osteoporosis (postmenopausal women) - abaloparatide [ID882]
In development [GID-TA10071] Expected publication date: TBC
-
Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]
In development [GID-TAG479] Expected publication date: TBC
-
Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]
In development [GID-TA10171] Expected publication date: TBC
-
Peramivir for treating influenza [ID828]
In development [GID-TA10155] Expected publication date: TBC
-
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
In development [GID-TA10177] Expected publication date: TBC
-
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
In development [GID-TA10159] Expected publication date: TBC
-
Lenalidomide for untreated follicular lymphoma ID1245
In development [GID-TA10308] Expected publication date: TBC
-
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467
In development [GID-TA10353] Expected publication date: TBC
-
Constipation (opioid induced) - methylnaltrexone bromide [ID700]
In development [GID-TA10003] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]
In development [GID-TA10008] Expected publication date: TBC
-
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
In development [GID-TA10236] Expected publication date: TBC
-
Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]
In development [GID-TA10028] Expected publication date: TBC
-
Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487
In development [GID-TA10437] Expected publication date: TBC
-
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997
In development [GID-TA10382] Expected publication date: TBC
-
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]
In development [GID-TA10338] Expected publication date: TBC
-
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
In development [GID-TA10151] Expected publication date: TBC
-
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]
In development [GID-TA10154] Expected publication date: TBC
-
Renal cell carcinoma - sunitinib [ID1076]
In development [GID-TA10166] Expected publication date: TBC
-
Osteoarthritis - diacerein [ID332]
In development [GID-TAG250] Expected publication date: TBC
-
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172
In development [GID-TA10394] Expected publication date: TBC
-
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
In development [GID-TA10404] Expected publication date: TBC
-
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
In development [GID-TA10337] Expected publication date: 19 February 2020
-
Pacritinib for treating myelofibrosis [ID880]
In development [GID-TA10133] Expected publication date: TBC
-
Atherothrombotic events - vorapaxar [ID616]
In development [GID-TAG493] Expected publication date: TBC
-
Head and neck cancer - intensity modulated radiotherapy [ID15]
In development [GID-TAG397] Expected publication date: TBC
-
Glaucoma - lerdelimumab (CAT-152) [ID383]
In development [GID-TAG381] Expected publication date: TBC
-
Breast cancer (brain metastases) - etirinotecan pegol [ID881]
In development [GID-TA10066] Expected publication date: TBC
-
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
In development [GID-TA10375] Expected publication date: TBC
-
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
In development [GID-TA10570] Expected publication date: 17 November 2021
-
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588
In development [GID-TA10507] Expected publication date: TBC
-
Lifitegrast for treating dry eye disease [ID1229]
In development [GID-TA10196] Expected publication date: TBC
-
Abicipar pegol for treating wet age-related macular degeneration ID1533
In development [GID-TA10511] Expected publication date: TBC
-
Psoriasis - briakinumab (suspended) [ID65]
In development [GID-TAG412] Expected publication date: TBC
-
Osteoarthritis - naproxcinod [ID417]
In development [GID-TAG426] Expected publication date: TBC
-
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
In development [GID-TAG418] Expected publication date: TBC
-
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]
In development [GID-TAG456] Expected publication date: TBC
-
Leukaemia (acute lymphoblastic) - dasatinib [ID386]
In development [GID-TAG399] Expected publication date: TBC
-
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]
In development [GID-TAG398] Expected publication date: 01 January 2011
-
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
In development [GID-TAG414] Expected publication date: TBC
-
Diabetic foot ulcers - new treatments [ID381]
In development [GID-TAG371] Expected publication date: TBC
-
Venous leg ulcers - new treatments [ID394]
In development [GID-TAG370] Expected publication date: TBC
-
Venous thromboembolism (VTE) - ximelagatran [ID396]
In development [GID-TAG378] Expected publication date: TBC
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC
-
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509
In development [GID-TA10413] Expected publication date: TBC
-
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940
In development [GID-TA10397] Expected publication date: TBC